Fisetin protects against cardiac cell death through reduction of ROS production and caspases activity

Abstract

fisetin treatment during the reoxygenation phase to mimic medication following surgery or dissolution of the thrombotic clot-our results are concordant. Our data also suggest that fisetin may have roles beyond cardiac protection, promoting cardiomyocyte proliferation and stimulating cardiomyocyte maturation. Further studies of cyclin-CDK complexes expression, degradation, phosphorylation activity and cellular localization would allow to better understand the effect of fisetin on cell cycle and DNA repair. Summing up, we showed that fisetin protects cardiomyocytes from oxidative damage, and that further research could enable the establishment of protocols for myocardial regeneration. These findings demonstrate the value of fisetin as a candidate drug for the repositioning in MI treatment, by inhibiting ischemic damage following MI and overcoming IRI. Methods Brief protocol descriptions can be found hereunder. Detailed methods are described in the Supplementary Material Supplementary Methods. prediction of candidate drugs for repositioning. Candidate compounds were identified through the integrated matching of zebrafish heart regeneration expression signatures against expression signatures obtained from drug-treated cell lines in the Connectivity Map database (CMap, build 2), which contains more than 7 K expression profiles representing more than 1.3 K compounds 58. Before implementing that procedure, we mapped gene sequences from zebrafish to humans 59 and we developed an algorithm for matching multiple regeneration signatures to CMap drug signatures. Our prediction pipeline provided a statistically-ranked, integrated list of compounds predicted to have positive, pro-regeneration potential (Supplementary Methods). chemicals. Fisetin (3,3′,4′,7-Tetrahydroxyflavone, F4043) was purchased from Sigma-Aldrich (St Louis, MO, USA). Drug was dissolved in DMSO to a stock concentration of 100 mM. The final DMSO concentration in cell culture medium never exceeded 0.1% 60 .

Fisetin Inhibits NLRP3 Inflammasome by Suppressing TLR4/MD2-Mediated Mitochondrial ROS Production

“…These studies demonstrate the occurrence of crosstalk between the NLRP3 inflammasome and mtROS and suggest that targeting mtROS by the elimination of damaged mitochondria could be a promising therapeutic strategy for NLRP3 inflammasome-related immune disorders. Interestingly, a previous study demonstrated that fisetin prevents the generation of intracellular ROS in osteoclast differentiation [ 44 ] and cardiac cell death [ 45 ], indicating its antioxidative effects in various diseases. In this study, fisetin inhibited the LPS/ATP-induced activation of the NLRP3 inflammasome by inhibiting the depolarization of mitochondrial membrane potential and subsequent production of mtROS.…”

Hyperoside protects cardiomyocytes against hypoxia‑induced injury via upregulation of microRNA‑138

“…Hypoxia is a common condition in numerous cardiovascular events, such as ischemic heart disease, high altitude heart disease and cyanotic congenital heart disease ( 1 ). When subjected to hypoxia, cardiomyocytes develop disorders of mitochondria, membrane and lysosomes, leading to the initiation of the caspase cascade and activation of the Bcl-2 family ( 19 ). Oxidative stress and apoptosis are key mechanisms underlying hypoxia-induced injury ( 20 ) and are primary targets of Hyp ( 16 ).…”

Oxidative Stress in Ischemic Heart Disease

“…It also reduces ROS formation, activates caspases, protects from DNA damage, and ultimately inhibits apoptosis. Fisetin is a very promising drug for protection against ischemic damage after myocardial infarction and for counteracting ischemia reperfusion injury because it can, in addition, activate genes involved in cell proliferation [ 263 ].…”